FDA Approves New Drug to Prevent RSV in Babies and Toddlers

Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. “RSV can cause serious disease in infants…

Read the full article here

Related Articles